會(huì)員.png)
14
Cellctis 公司在大范圍核酸酶基因工程研究領(lǐng)域處于地位，它的許多研究成果被成功運(yùn)用于多種作物上，能對(duì)基因序列進(jìn)行插入，刪除或者改性操作，使得植物能表達(dá)出新的性狀（比如抗旱，提高營養(yǎng)成分，抗病害等）目前有四個(gè)子公司Cellectis bioresearch, Cellectis therapeutics, Ectycell,Cellectis plant sciences服務(wù)于人類健康，生物產(chǎn)業(yè)，農(nóng)業(yè)生物技術(shù)和干細(xì)胞領(lǐng)域，主要的工程技術(shù)是基因工程和蛋白工程技術(shù)。
- Worldwide pioneer in Genome engineering
- Established in 1999, listed on the NYSE-Euronext Alternext market in Paris since 2007
- Revenues 2010: € 15.8 M （70% sales from abroad）
- Staff: 152 including 60 PhDs
- 4 subsidiaries: Cellectis bioresearch, Cellectis therapeutics,Ectycell, Cellectis plant sciences
- Applications: human health, research and biomanufacturing, agrobiotechnology, stem cells
- Main technologies: Genome engineering, Protein engineering
- IP portfolio: 83 patents granted plus over 260 pending
- Location: Paris （France）, Evry （France）, Saint-Paul, Minnesota （USA）, Cambridge, Massachussets （USA）
